Skip to main content
. 2017 Dec 1;3(3):555–572. doi: 10.1016/j.ekir.2017.11.019

Table 5.

miRNAs identified in this work that are associated with kidney function and/or diabetes

miRNA Kidney function Diabetes function Targeted pathways (validated)
hsa-let-7a-1-5p LN, RCC, DN DN TGF-β (TGFBRI)
hsa-let-7c-5p Rfib, ESRD T1D (ESRD) TGF-β (TGF-βRI)
hsa-miR-101-1-3p AKI
hsa-miR-10a-5p AKI,AKR T2D (Glucose regulation) cAMP (CREB1)
hsa-miR-10b-5p RCC, AKR, AKI Insulin resistance Apoptosis (BCL2L11)
hsa-miR-122-5p RCC T2D (insulin resistance, obesity)
hsa-miR-124-1-3p RCC T2D (Glucagon, gastric bypass treatment)
hsa-miR-125a-5p PCKD, DN T2D,DN IL-6R
hsa-miR-125b-1-5p CKD, AKI T1D (β-cell)
hsa-miR-130a-3p DN T1D
hsa-miR-133a-1-3p T1D (β-cell) FoxO/AMPK
hsa-miR-141-3p RCC, DN DN, Obesity-induced DM PTEN (PTEN), TGF-β (ZEB1/2), IGF2
hsa-miR-142-3p AKI, AKR T2D TGF-β (TGFβRI)
hsa-miR-144-3p IgA-N T2D (Micro-vascular)
hsa-miR-148a-3p LN-RD T2D (β-cell) PTEN (PTEN)
hsa-miR-152-3p T2D (Insulin) PTEN (PTEN)
hsa-miR-181b-1-5p AKR, Nephron development Glucose homeostasis, insulin resistance Six2
hsa-miR-182-5p AKI, PKD T2D (Insulin)
hsa-miR-183-5p T2D (β-cell)
hsa-miR-185-5p AKR β-cell Cytokine/IGF (SOCS3)
hsa-miR-188-5p AKI, RIRI
hsa-miR-192-5p AKI, RIRI, DN T2D (β-cell), DN
hsa-miR-197-3p Glycemic impairment
hsa-miR-200a-3p Rfib, DN DN, insulin TGF-β (TGFβRI), IGF
hsa-miR-200c-3p Glomerular cell function T2D (Endo) TGF-β (ZEB1/2)
hsa-miR-21-5p Rfib, DN, IgA-N T1D, T2D TGF-β (SMAD7), PTEN (PTEN)
hsa-miR-22-3p Rfib T1D TGF-β (BMP-7,6)
hsa-miR-23b-3p RCC T1D (β-cell) PTEN (PTEN), Apoptosis (DP5)
hsa-miR-26a-1-5p Podocyte injury, LN-RD, DN T2D (Glucose/Insulin) IGF (GSK3B), TGF-β (CTGF)
hsa-miR-26b-5p AKI T2D (β-cell- Insulin) PTEN (PTEN)
hsa-miR-27b-3p Glomerular injury T2D (Islet) TGF-B (gremlin 1)
hsa-miR-28-3p RCC, DN T1D (DN), T2D
hsa-miR-29b-1-3p Rfib T2D (Hyperglycemia)
hsa-miR-29c-3p ESRD T1D (ESRD) TGF-β (targeted by)
hsa-miR-30a-5p AKI, NS T2D (Glucose, β-cell) Notch (Notch1)
hsa-miR-30b-5p LN-RD β-cell dysfunction
hsa-miR-30c-1-5p AKI, DN DN TGF-β (CTGF)
hsa-miR-30d-5p AKI, PKD T2D, β-cells (insulin) Insulin (MAP4K4)
hsa-miR-31-5p PCKD T1D (serum), T2D (micro-vascular)
hsa-miR-335-5p Renal senescence, DN T1D (DN) SOD2
hsa-miR-342-3p AKI T1D,T2D (PBMCs)
hsa-miR-362-5p RIRI GDM
hsa-miR-363-3p DN T1D (DN)
hsa-miR-373-3p DN T1D (DN)
hsa-miR-451a-5p DN DN
hsa-miR-486-1-5p DN, CKD, AKI, IgA-N T2D, T1D (DN)
hsa-miR-660-5p DN T1D (DN)
hsa-miR-9-1-3p T1D (serum)
hsa-miR-941-1-3p Insulin (9)
hsa-miR-96-5p PKD, RCC T2D, β-cells (insulin) IGF (synaptotagmin-like 4)
hsa-miR-99a-5p AKR,RCC Glucose/insulin regulation mTOR
hsa-miR-99b-5p AKR T2D (IGT) TGF-β (EMT)

AKR, Acute Kidney Rejection/Renal Graft Rejection; AKI, acute kidney injury; CKD, chronic kidney disease; DIKD, drug induced kidney damage, DN, diabetic nephropathy; Endo, endothelial dysfunction; EMT, epithelial–mesenchymal transition; EndMT, endothelial-mesenchymal transition; ESRD, end-stage renal disease; GD, gestational diabetes mellitus; IgA-N, IgA nephropathy; IGF, insulin-like growth factor; IGT, impaired glucose tolerance; LN-RD, lupus nephritis induced renal damage; MA, microalbuminuria; miRNA, microRNA; NS, nephrotic syndrome; PCKD, poly-cystic kidney disease; PKD, progressive kidney disease; PTEN, phosphatase and tensin homolog; RCC, renal cell carcinoma; Rfib, renal fibrosis: RIRI, renal ischemia-reperfusion injury; TGF, transforming growth factor; T1D, type 1 diabetes mellitus; T2D), type 2 diabetes mellitus.

See references 23, 24,40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144.